BACKGROUND AND PURPOSE: Abrupt discontinuation of nicotine, the main psychoactive component in tobacco, induces a withdrawal syndrome in nicotine-dependent animals, consisting of somatic and affective signs, avoidance of which contributes to drug maintenance. While blockade of fatty acid amide hydrolase, the primary catabolic enzyme of the endocannabinoid arachidonoylethanolamine (anandamide), exacerbates withdrawal responses in nicotine-dependent mice, the role of monoacylglycerol lipase (MAGL), the main hydrolytic enzyme of a second endocannabinoid 2-arachidonylglycerol (2-AG), in nicotine withdrawal remains unexplored. EXPERIMENTAL APPROACH: To evaluate the role of MAGL enzyme inhibition in nicotine withdrawal, we initially performed a genetic correlation approach using the BXD recombinant inbred mouse panel. We then assessed nicotine withdrawal intensity in the mouse after treatment with the selective MAGL inhibitor, JZL184, and after genetic deletion of the enzyme. Lastly, we assessed the association between genotypes and smoking withdrawal phenotypes in two human data sets. KEY RESULTS: BXD mice displayed significant positive correlations between basal MAGL mRNA expression and nicotine withdrawal responses, consistent with the idea that increased 2-AG brain levels may attenuate withdrawal responses. Strikingly, the MAGL inhibitor, JZL184, dose-dependently reduced somatic and aversive withdrawal signs, which was blocked by rimonabant, indicating a CB1 receptor-dependent mechanism. MAGL-knockout mice also showed attenuated nicotine withdrawal. Lastly, genetic analyses in humans revealed associations of the MAGL gene with smoking withdrawal in humans. CONCLUSIONS AND IMPLICATIONS: Overall, our findings suggest that MAGL inhibition maybe a promising target for treatment of nicotine dependence.
BACKGROUND AND PURPOSE: Abrupt discontinuation of nicotine, the main psychoactive component in tobacco, induces a withdrawal syndrome in nicotine-dependent animals, consisting of somatic and affective signs, avoidance of which contributes to drug maintenance. While blockade of fatty acid amide hydrolase, the primary catabolic enzyme of the endocannabinoid arachidonoylethanolamine (anandamide), exacerbates withdrawal responses in nicotine-dependent mice, the role of monoacylglycerol lipase (MAGL), the main hydrolytic enzyme of a second endocannabinoid 2-arachidonylglycerol (2-AG), in nicotine withdrawal remains unexplored. EXPERIMENTAL APPROACH: To evaluate the role of MAGL enzyme inhibition in nicotine withdrawal, we initially performed a genetic correlation approach using the BXD recombinant inbred mouse panel. We then assessed nicotine withdrawal intensity in the mouse after treatment with the selective MAGL inhibitor, JZL184, and after genetic deletion of the enzyme. Lastly, we assessed the association between genotypes and smoking withdrawal phenotypes in two human data sets. KEY RESULTS: BXD mice displayed significant positive correlations between basal MAGL mRNA expression and nicotine withdrawal responses, consistent with the idea that increased 2-AG brain levels may attenuate withdrawal responses. Strikingly, the MAGL inhibitor, JZL184, dose-dependently reduced somatic and aversive withdrawal signs, which was blocked by rimonabant, indicating a CB1 receptor-dependent mechanism. MAGL-knockout mice also showed attenuated nicotine withdrawal. Lastly, genetic analyses in humans revealed associations of the MAGL gene with smoking withdrawal in humans. CONCLUSIONS AND IMPLICATIONS: Overall, our findings suggest that MAGL inhibition maybe a promising target for treatment of nicotine dependence.
Authors: Adrianna Mendrek; John Monterosso; Sara L Simon; Murray Jarvik; Arthur Brody; Richard Olmstead; Catherine P Domier; Mark S Cohen; Monique Ernst; Edythe D London Journal: Addict Behav Date: 2005-07-11 Impact factor: 3.913
Authors: T Sugiura; S Kondo; A Sukagawa; S Nakane; A Shinoda; K Itoh; A Yamashita; K Waku Journal: Biochem Biophys Res Commun Date: 1995-10-04 Impact factor: 3.575
Authors: D H Malin; J R Lake; V A Carter; J S Cunningham; K M Hebert; D L Conrad; O B Wilson Journal: Psychopharmacology (Berl) Date: 1994-06 Impact factor: 4.530
Authors: Pretal P Muldoon; Lois S Akinola; Joel E Schlosburg; Aron H Lichtman; Laura J Sim-Selley; Anu Mahadevan; Benjamin F Cravatt; M Imad Damaj Journal: Neuropharmacology Date: 2020-05-30 Impact factor: 5.250
Authors: Dan P Covey; Hannah M Dantrassy; Samantha E Yohn; Alberto Castro; P Jeffrey Conn; Yolanda Mateo; Joseph F Cheer Journal: Neuropsychopharmacology Date: 2018-06-01 Impact factor: 7.853
Authors: Asti Jackson; Deniz Bagdas; Pretal P Muldoon; Aron H Lichtman; F Ivy Carroll; Mark Greenwald; Michael F Miles; M Imad Damaj Journal: Neuropharmacology Date: 2017-03-07 Impact factor: 5.250
Authors: Maria Scherma; Anna Lisa Muntoni; Miriam Melis; Liana Fattore; Paola Fadda; Walter Fratta; Marco Pistis Journal: Psychopharmacology (Berl) Date: 2016-01-04 Impact factor: 4.530
Authors: Caitlin E Carey; Arpana Agrawal; Bo Zhang; Emily D Conley; Louisa Degenhardt; Andrew C Heath; Daofeng Li; Michael T Lynskey; Nicholas G Martin; Grant W Montgomery; Ting Wang; Laura J Bierut; Ahmad R Hariri; Elliot C Nelson; Ryan Bogdan Journal: J Abnorm Psychol Date: 2015-11
Authors: Malte Feja; Martin P K Leigh; Ajay N Baindur; Justin J McGraw; Ken T Wakabayashi; Benjamin F Cravatt; Caroline E Bass Journal: Neuropharmacology Date: 2019-10-17 Impact factor: 5.250